Enhanced Genomics partnership unlocks hidden Alzheimer’s targets through breakthrough 3D multi-omics
Enhanced Genomics has partnered with Cambridge University’s ALBORADA Drug Discovery Institute to identify novel therapeutic targets for Alzheimer’s disease using advanced 3D multi-omics technology. The collaboration has already yielded multiple previously undetectable targets, potentially accelerating drug discovery timelines across neurodegenerative diseases.
A strategic partnership between Enhanced Genomics and The ALBORADA Drug Discovery Institute at the University of Cambridge has successfully identified novel therapeutic targets for Alzheimer’s disease using cutting-edge 3D multi-omics technology. The collaboration demonstrates the transformative potential of three-dimensional genomic analysis in accelerating drug discovery processes and improving success rates across neurodegenerative disease research.
Proprietary technology maps hidden gene networks
The partnership leveraged Enhanced Genomics’ proprietary Promoter Capture Hi-C technology to map long-range chromatin interactions, revealing previously hidden gene regulatory mechanisms driving Alzheimer’s pathology. This sophisticated approach identified several novel therapeutic targets whilst simultaneously corroborating existing targets reported in scientific literature, opening new avenues for therapeutic intervention.
Enhanced Genomics’ 3D multi-omics platform combines multi-omic data analysis with expert knowledge to harness the full potential of the non-coding genome. Unlike conventional genomic approaches, this technology detects targets that remain invisible through traditional methodologies, offering unprecedented insights into disease mechanisms.
“Our partnership with The ALBORADA Drug Discovery Institute showcases the transformative power of 3D multi-omics in drug discovery,” said Dr Dan Turner, CSO of Enhanced Genomics. “By harnessing our unique platform, we have not only accelerated the target discovery process but also unveiled new therapeutic possibilities by harnessing the full potential of the non-coding genome.”
Industry collaboration drives Alzheimer’s research momentum
The ALBORADA Drug Discovery Institute, funded by Alzheimer’s Research UK, focuses on developing next-generation treatments for dementia-causing diseases. Dr John Skidmore, CSO at The ALBORADA Drug Discovery Institute, emphasised the collaboration’s significance: “Using the insights provided by Enhanced’s technology, we have gained new actionable targets operating by a range of mechanisms. This could significantly advance our ability to develop effective treatments for Alzheimer’s disease.”
Dr Julia Dudley, Head of Strategic Programmes at Alzheimer’s Research UK, highlighted the broader implications: “There has been unprecedented progress in dementia drug development, but we must keep up the momentum to help find new treatments and, in time, a cure. Partnerships like these are bringing the worlds of academia and industry closer together, helping to speed up the discovery of potential new treatments that people with dementia so desperately need.”
Expanding applications across neurodegenerative diseases
Enhanced Genomics and The ALBORADA Drug Discovery Institute are now exploring opportunities to expand their partnership to other neurodegenerative diseases. The Cambridge-based biotechnology company remains open to partnerships with pharmaceutical and biotech firms interested in utilising its 3D multi-omics platform in their drug discovery programmes.
For more information, visit: www.enhancedgenomics.com
Dr Dan Turner, CSO of Enhanced Genomics | Dr John Skidmore, CSO at The ALBORADA Drug Discovery Institute | Dr Julia Dudley, Head of Strategic Programmes at Alzheimer’s Research UK
